Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Fund Type: SICAV
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: International

Candriam Equities L Biotechnology

+ Add to Watchlist

DEXEBTL:LX

557.85 USD 7.39 1.34%

As of 00:59:30 ET on 02/25/2015.

Snapshot for Candriam Equities L Biotechnology (DEXEBTL)

Year To Date: +9.92% 3-Month: +11.99% 3-Year: +41.11% 52-Week Range: 353.00 - 557.85
1-Month: +5.05% 1-Year: +24.89% 5-Year: - Beta vs BTK: 0.94

Mutual Fund Chart for DEXEBTL

No chart data available.
  • DEXEBTL:LX 557.85
  • 1M
  • 1Y
Interactive DEXEBTL Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for DEXEBTL

Candriam Equities L - Biotechnology is a SICAV incorporated under the laws of Luxembourg. The Fund's objective is capital appreciation. The Fund invests in global biotechnology stocks. Because the sector is currently experiencing the highest growth in the U.S., at least two-thirds of the Fund's assets will be invested in U.S. biotechnology stocks.

Inception Date: 03-21-2011 Telephone: 352-254-3431
Managers: RUDI VAN DEN EYNDE
Web Site: www.candriam.com

Fundamentals for DEXEBTL

NAV (on 2015-02-25) 557.85
Assets (M) (on 2015-02-25) 841.19
Fund Leveraged N
Minimum Investment 0.00
Minimum Subsequent Investment -

Dividends for DEXEBTL

No dividends reported

Fees & Expenses for DEXEBTL

Front Load 3.50
Back Load 0.00
Current Mgmt Fee 1.50
Redemption Fee 0.00
12b1 Fee -
Expense Ratio -

Top Fund Holdings for DEXEBTL

Filing Date: 12/31/2014
Name Position Value % of Total
Celgene Corp 547,000 61,187,420 8.592%
Amgen Inc 355,000 56,547,950 7.941%
Biogen Idec Inc 154,000 52,275,300 7.341%
Gilead Sciences Inc 506,000 47,695,560 6.698%
Alexion Pharmaceuticals Inc 168,000 31,085,040 4.365%
Regeneron Pharmaceuticals Inc 73,000 29,948,250 4.206%
Vertex Pharmaceuticals Inc 180,000 21,384,000 3.003%
Illumina Inc 95,000 17,535,100 2.462%
BioMarin Pharmaceutical Inc 174,000 15,729,600 2.209%
Incyte Corp 214,000 15,645,540 2.197%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil